Premium
Expression mapping at 12p12‐13 in advanced prostate carcinoma
Author(s) -
Kibel Adam S.,
Huagen John,
Guo Chan,
Isaacs William B.,
Yan Yan,
Pienta Kenneth J.,
Goodfellow Paul J.
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20060
Subject(s) - prostate cancer , biology , loss of heterozygosity , prostate , gene , cancer research , tumor suppressor gene , chromoplexy , locus (genetics) , cancer , genetics , pca3 , carcinogenesis , allele
We have previously mapped a putative prostate cancer tumor‐suppressor gene to a 1–2 Mb region of 12p12‐13. Initial work to identify the tumor suppressor at this locus focused on candidates previously implicated in malignancy; however, mutational and methylation analyses failed to identify significant genomic events. An alternative approach is to use expression analysis to prioritize the genes within the region of interest. This experimental design is based on the hypothesis that tumor‐suppressor genes demonstrate decreased expression in tumors compared to normals. Herein, we narrow the region of interest using deletion mapping data and employ expression analysis to prioritize the genes in the minimal deleted region. Highly informative polymorphic markers spanning our region were used to assess for loss of heterozygosity in 99 tumor and normal DNA pairs. The minimal region of deletion was determined to be approximately 500 kb bounded by D12S391 and A002Q26. Publically available databases place 7 genes within this minimal deletion region. An additional 3 genes lie just outside this minimal deletion region and could possibly be inactivated by deletion of promoter, 3′‐untranslated region sequences or alternative splice variants. Relative levels of expression of these 10 candidate genes were determined in 6 normal prostates, 5 local prostate tumors, 9 prostate lymph node metastases, 6 prostate cancer cell lines and 12 prostate cancer xenografts using quantitative RT‐PCR. DUSP16, FLJ10298 and BCLG were significantly downregulated in both clinical tumors and cultured prostate cancer tissue, indicating that one or all may be critical to initiation or progression of prostate carcinoma. © 2004 Wiley‐Liss, Inc.